2G12-Expressing B cell lines may aid in HIV carbohydrate vaccine design strategies

Journal of Virology

Volumn 87, Issue 4, 2013, Pages 2234-2241

  Doores, Katie J ^a,b   Huber, Michael ^a,b   Le, Khoa M ^a   Wang, Sheng Kai ^a   Doyle Cooper, Colleen ^a   Cooper, Anthony ^a   Pantophlet, Ralph ^c   Wong, Chi Huey ^a   Nemazee, David ^a   Burton, Dennis R ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARBOHYDRATE VACCINE; GLYCAN; HUMAN IMMUNODEFICIENCY VIRUS 1 ENVELOPE GLYCOPROTEIN; OLIGOMANNOSE GLYCAN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG DESIGN; FUNGAL VIRULENCE; GERM CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CARBOHYDRATES; CELL LINE; DRUG DISCOVERY; GENE EXPRESSION; HIV ENVELOPE PROTEIN GP120; HIV-1; LYMPHOCYTE ACTIVATION; MICE;

EID: 84873854524     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02820-12     Document Type: Article

References (40)

1. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
2. Doores KJ, Burton DR. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
3. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
4. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
5. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
6. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
7. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
8. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
9. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028.
10. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
11. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
12. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
13. Dunlop DC, Bonomelli C, Mansab F, Vasiljevic S, Doores KJ, Wormald MR, Palma AS, Feizi T, Harvey DJ, Dwek RA, Crispin M, Scanlan CN. 2010. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 20:812-823.
14. Luallen RJ, Agrawal-Gamse C, Fu H, Smith DF, Doms RW, Geng Y. 2010. Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology 20:280-286.
15. Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y. 2008. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannosespecific gp120-binding antibodies. J. Virol. 82:6447-6457.
16. Clark BE, Auyeung K, Fregolino E, Parrilli M, Lanzetta R, De Castro C, Pantophlet R. 2012. A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. Chem. Biol. 19:254-263.
17. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, Wong CH. 2008. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. U. S. A. 105:3690-3695.
18. Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR. 2010. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17:357-370.
19. Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, Wormald MR, Finn MG, Burton DR, Wilson IA, Davis BG. 2010. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc. Natl. Acad. Sci. U. S. A. 107:17107-17112.
20. Doores KJ, Fulton Z, Huber M, Wilson IA, Burton DR. 2010. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomainexchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J. Virol. 84:10690-10699.
21. Huber M, Le KM, Doores KJ, Fulton Z, Stanfield RL, Wilson IA, Burton DR. 2010. Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J. Virol. 84:10700 -10707.
22. Ota T, Doyle-Cooper C, Cooper A, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Poignard P, Binley J, Chakrabarti BK, Schief W, Wyatt R, Burton DR, Nemazee D. 2012. Anti-HIV B cell lines as candidate vaccine biosensors. J. Immunol. 189: 4816-4824.
23. Nemazee DA, Burki K. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337: 562-566.
24. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:549-554.
25. Roux KH, Zhu P, Seavy M, Katinger H, Kunert R, Seamon V. 2004. Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol. Immunol. 41:1001-1011.
26. Strable E, Prasuhn DE, Jr, Udit AK, Brown S, Link AJ, Ngo JT, Lander G, Quispe J, Potter CS, Carragher B, Tirrell DA, Finn MG. 2008. Unnatural amino acid incorporation into virus-like particles. Bioconjug. Chem. 19:866-875.
27. Dunlop DC, Ulrich A, Appelmelk BJ, Burton DR, Dwek RA, Zitzmann N, Scanlan CN. 2008. Antigenic mimicry of the HIV envelope by AIDSassociated pathogens. AIDS 22:2214-2217.
28. Batista FD, Neuberger MS. 1998. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8:751-759.
29. Dal Porto JM, Haberman AM, Shlomchik MJ, Kelsoe G. 1998. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J. Immunol. 161:5373-5381.
30. Schief WR, Ban YE, Stamatatos L. 2009. Challenges for structure-based HIV vaccine design. Curr. Opin. HIV AIDS 4:431-440.
31. Bongini L, Fanelli D, Piazza F, De Los Rios P, Sandin S, Skoglund U. 2004. Freezing immunoglobulins to see them move. Proc. Natl. Acad. Sci. U. S. A. 101:6466-6471.
32. Roux KH, Strelets L, Michaelsen TE. 1997. Flexibility of human IgG subclasses. J. Immunol. 159:3372-3382.
33. Saphire EO, Stanfield RL, Crispin MD, Parren PW, Rudd PM, Dwek RA, Burton DR, Wilson IA. 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319:9-18.
34. Scanlan CN, Offer J, Zitzmann N, Dwek RA. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446:1038-1045.
35. Alam SM, Liao HX, Dennison SM, Jaeger F, Parks R, Anasti K, Foulger A, Donathan M, Lucas J, Verkoczy L, Nicely N, Tomaras GD, Kelsoe G, Chen B, Kepler TB, Haynes BF. 2011. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 85:11725-11731.
36. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
37. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structurefunction analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
38. Evans DW, Muller-Loennies S, Brooks CL, Brade L, Kosma P, Brade H, Evans SV. 2011. Structural insights into parallel strategies for germline antibody recognition of lipopolysaccharide from Chlamydia. Glycobiology 21:1049-1059.
39. Nguyen HP, Seto NO, MacKenzie CR, Brade L, Kosma P, Brade H, Evans SV. 2003. Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct. Biol. 10:1019-1025.
40. Baxendale HE, Johnson M, Stephens RC, Yuste J, Klein N, Brown JS, Goldblatt D. 2008. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin. Exp. Immunol. 151:51-60.